Flare Therapeutics has selected Simplicis Ledger™ as its primary compound and inventory management platform. The partnership shifts Flare Tx from person-dependent workflows to an automation-ready foundation for drug discovery.
Lean biotech teams often face operational fragility, where critical scientific data depends on a single individual or manual workarounds. Flare Therapeutics identified this bottleneck and chose Ledger™ to connect physical inventory with digital automation.
“We reached a point where our system required more human babysitting and workarounds than I could reliably provide without help,” said Caitlin, Compound Management Lead at Flare Therapeutics. “As the primary compound manager in the company, I needed infrastructure we could actually trust. Ledger™ gives us that, allowing us to scale without increasing headcount or overhead.”
Before implementation, Flare Tx managed workflows such as assay-ready plate production and acoustic dispensing with significant manual oversight and custom IT workarounds. These offline processes created operational risk and limited cross-training.
Working in analytical science?
Register for a FREE Separation Science account to subscribe to the Separation Science Newsletter.
By implementing Ledger™ and Ledger™ Acoustic, Flare Tx achieved end-to-end transparency with real-time alignment between inventory state and assay execution. The company established automation-ready workflows through integration with acoustic dispensing platforms, eliminating manual file handling. The unified system now supports predictable workflow management and broader team adoption.
“Flare Tx’s move reflects a broader biotech trend: the shift from brittle, workaround-driven systems to 'Scientific Infrastructure' that supports velocity,” remarks James Craven, Chief Commercial Officer at Simplicis. “Ledger™ was designed to remove the hidden friction between inventory, automation, and people.”
Simplicis provides laboratory information management systems designed to optimize workflows, enhance data management, and drive innovation. The Ledger™ platform targets the evolving needs of biotechnology and pharmaceutical organizations and supports efficiency and scalability in research environments.
Flare Therapeutics, launched in 2021, focuses on deciphering the biology of transcription factors to develop small molecule medicines. The company has identified druggable “switch sites” that regulate transcription factors and address disease-causing mutations.
This article is based on a press release issued by Simplicis.
